注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   癌症   >   TSG101 Antibody   

TSG101 Antibody

Purified Mouse Monoclonal Antibody (Mab)

     
  • 1 - TSG101 Antibody AM8662b
    All lanes: Anti-TSG101 Antibody at 1:1000 dilution Lane 1: K562 whole cell lysate Lane 2: Jurkat whole cell lysate Lane 3: HepG2 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Mouse IgG, (H+L), Peroxidase conjugated (ASP1613) at 1/8000 dilution. Observed band size: 44 KDa Blocking/Dilution buffer: 5% NFDM/TBST.
  • 产品详情
  • 文献引用 : 1
  • 实验流程
  • 背景知识
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
WB, E
Primary Accession Q99816
Reactivity Human
Host Mouse
Clonality monoclonal
Isotype IgG1,κ
Clone Names 1883CT788.47.15.46
Calculated MW 43944 Da
Additional Information
Gene ID 7251
Other Names Tumor susceptibility gene 101 protein, ESCRT-I complex subunit TSG101, TSG101
Target/Specificity This antibody is generated from a mouse immunized with a recombinant protein from human.
Dilution WB~~1:1000
E~~Use at an assay dependent concentration.
Format Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
PrecautionsTSG101 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name TSG101
Function Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413). It may also play a role in the extracellular release of microvesicles that differ from the exosomes (PubMed:22315426).
Cellular Location Cytoplasm. Early endosome membrane; Peripheral membrane protein; Cytoplasmic side. Late endosome membrane; Peripheral membrane protein. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Midbody, Midbody ring. Nucleus. Note=Mainly cytoplasmic. Membrane- associated when active and soluble when inactive. Nuclear localization is cell cycle-dependent. Interaction with CEP55 is required for localization to the midbody during cytokinesis
Tissue Location Heart, brain, placenta, lung, liver, skeletal, kidney and pancreas
Research Areas

For Research Use Only. Not For Use In Diagnostic Procedures.

BACKGROUND

Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses.

REFERENCES

Li L.,et al.Cell 88:143-154(1997).
Li L.,et al.Cell 93:661-661(1998).
Gayther S.A.,et al.Oncogene 15:2119-2126(1997).
Lee M.P.,et al.Cancer Res. 57:3131-3134(1997).
Wagner K.-U.,et al.Oncogene 17:2761-2770(1998).

FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价